MedTrace Logo

Safety and Efficacy Study of Albiglutide in Type 2 Diabetes

NCT00849017 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 309

Last updated 2017-01-09

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether albiglutide is effective in the treament of patients with type 2 diabetes.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

BIOLOGICAL

albiglutide

albiglutide weekly injection

BIOLOGICAL

albiglutide uptitration

albiglutide uptitration at week 12

BIOLOGICAL

placebo

matching albiglutide placebo weekly injection

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2011-11-30
Completion
2013-02-28

Countries

  • United States
  • Mexico
  • South Africa

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00849017 on ClinicalTrials.gov